Study Design and Patient Population

The international trial enrolled 639 patients whose disease had returned or failed to respond to prior therapy, the majority of whom had previously received a covalent BTK inhibitor. Participants were randomized to receive either the three-drug regimen—pirtobrutinib plus venetoclax and rituximab—or the standard venetoclax–rituximab combination. In the investigational arm, pirtobrutinib and rituximab were initiated first, with venetoclax introduced after the initial treatment cycles.

Efficacy Outcomes

At a median follow-up of just over two years, the addition of pirtobrutinib significantly prolonged progression-free survival (PFS), the study’s primary endpoint. Patients receiving the triplet regimen experienced a 45% reduction in the risk of disease progression or death compared with those on standard therapy. Median PFS had not yet been reached in the experimental group, whereas it was approximately 40 months in the control arm.

Benefits were consistently observed across predefined subgroups, including individuals previously treated with BTK inhibitors and those with high-risk disease features such as TP53 mutations or complex cytogenetics. In a secondary analysis focusing on second-line treatment after prior BTK inhibitor therapy, the triplet regimen showed particularly notable durability, with substantially higher PFS rates at two years compared with the standard approach.

While overall survival data remain immature, early trends did not yet demonstrate a statistically significant difference. However, time to next treatment favored the pirtobrutinib-containing regimen, suggesting more sustained disease control.

Safety Findings

The safety profile of the combination therapy was generally aligned with expectations for the individual agents. Rates of grade 3 or higher adverse events were similar between treatment arms. Common serious events included neutropenia, though other clinically relevant toxicities—such as atrial fibrillation, hypertension, and bleeding—remained relatively infrequent.

Treatment discontinuation due to adverse effects occurred at comparable rates in both groups. Notably, the addition of pirtobrutinib appeared to reduce tumor lysis syndrome risk in some patients by allowing risk category downgrades during therapy, potentially simplifying clinical management.

Clinical Implications

Investigators highlighted the importance of time-limited treatment strategies in CLL, which can offer patients meaningful periods without therapy. The findings suggest that incorporating pirtobrutinib into such regimens may deepen and prolong responses, particularly in patients who have already been exposed to BTK inhibitors—a common scenario in modern practice.

Experts involved in the trial noted that enhancing second-line treatment options is increasingly critical, as many patients receive only a limited number of therapy lines over the course of their disease. The results from BRUIN CLL-322 therefore have the potential to reshape standard approaches in this setting.

Next Steps

Lilly plans to submit the data to regulatory authorities worldwide with the aim of expanding the approved use of pirtobrutinib. Additional Phase 3 studies evaluating the agent across different stages of CLL and SLL are ongoing.

The full dataset will be presented at the 2026 European Hematology Association Annual Meeting, where it has been selected for a late-breaking session—an indication of its perceived clinical significance.